Were Paolo Tonucci’s Marex Group (MRX) share sales pre-planned?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 plan entered into on October 22, 2025. Such plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later market-sensitive information.

Marex Group (MRX) executive sells 16,666 shares in planned trade

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Marex Group plc officer Paolo Tonucci reported selling 16,666 Ordinary Shares of the company on April 13, 2026 in open-market transactions. The sales occurred in three blocks of 6,760, 5,829 and 4,077 shares at weighted average prices of $50.6012, $51.5564 and $52.3578, respectively. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan entered into on October 22, 2025, indicating they were scheduled in advance. Following the sales, Tonucci directly holds 1,363,357 Ordinary Shares, which include 286,871 shares underlying deferred bonus plan awards that each convert into one Ordinary Share upon vesting and settlement.

Insider Trade Summary 10b5-1

Net Seller: 16,666 shares ($856,049)

Net Sell 3 txns

Insider Tonucci Paolo

Role See Remarks

Sold 16,666 shs ($856K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,760	$50.6012	$342K
Sale	Ordinary Shares	5,829	$51.5564	$301K
Sale	Ordinary Shares	4,077	$52.3578	$213K

Holdings After Transaction: Ordinary Shares — 1,373,263 shares (Direct)

Footnotes (1)

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $50.07 to $51.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $51.08 to $52.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.09 to $52.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Key Figures

Shares sold (total): 16,666 shares Block 1 sale: 6,760 shares at $50.6012 Block 2 sale: 5,829 shares at $51.5564 +3 more

6 metrics

Shares sold (total) 16,666 shares Ordinary Shares sold on April 13, 2026

Block 1 sale 6,760 shares at $50.6012 Weighted average price, Ordinary Shares

Block 2 sale 5,829 shares at $51.5564 Weighted average price, Ordinary Shares

Block 3 sale 4,077 shares at $52.3578 Weighted average price, Ordinary Shares

Shares owned after sale 1,363,357 shares Directly held Ordinary Shares following transactions

Deferred bonus awards 286,871 shares Shares underlying deferred bonus plan awards included in holdings

Key Terms

Rule 10b5-1 plan, weighted average price, deferred bonus plan awards, Ordinary Shares

4 terms

Rule 10b5-1 plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into..."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

deferred bonus plan awards financial

"The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards..."

Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.

Ordinary Shares financial

"The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards..."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tonucci Paolo

(Last)

(First)

(Middle)

C/O MAREX GROUP PLC, 155 BISHOPSGATE

(Street)

LONDON

UNITED KINGDOM

EC2M 3TQ

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Marex Group plc [ MRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/13/2026		S⁽¹⁾		6,760	D	$50.6012⁽²⁾	1,373,263	D
Ordinary Shares	04/13/2026		S⁽¹⁾		5,829	D	$51.5564⁽³⁾	1,367,434	D
Ordinary Shares	04/13/2026		S⁽¹⁾		4,077	D	$52.3578⁽⁴⁾	1,363,357⁽⁵⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $50.07 to $51.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $51.08 to $52.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.09 to $52.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Remarks:

Chief Strategist and CEO, Capital Markets

	/s/ Scott Linsley as Attorney-in-Fact, for Paolo Tonucci	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Marex Group (MRX) officer Paolo Tonucci report in this Form 4?

He reported selling 16,666 Marex Group Ordinary Shares in open-market transactions. The trades were split into three blocks on April 13, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan established in October 2025.

How many Marex Group (MRX) shares did Paolo Tonucci sell and at what prices?

He sold 16,666 Ordinary Shares in three blocks: 6,760 shares at a weighted average of $50.6012, 5,829 shares at $51.5564, and 4,077 shares at $52.3578. Each block reflects multiple trades within disclosed price ranges.

How many Marex Group (MRX) shares does Paolo Tonucci own after these sales?

After the reported transactions, he directly owns 1,363,357 Marex Group Ordinary Shares. This total includes both currently held shares and 286,871 shares underlying deferred bonus plan awards that convert into Ordinary Shares upon vesting and settlement.

What are the deferred bonus plan awards mentioned in the Marex Group (MRX) filing?

They are awards that give a contingent right to receive Marex Ordinary Shares in the future. The filing notes 286,871 shares underlying deferred bonus plan awards, each representing one Ordinary Share upon vesting and settlement, and they are included in Tonucci’s reported holdings.

How were the Marex Group (MRX) sale prices for Paolo Tonucci calculated?

For each block, the reported price is a weighted average across multiple trades. The underlying trades occurred within specific ranges, and Tonucci has undertaken to provide detailed per-trade pricing information to the issuer, security holders, or SEC staff upon request.